6.
Lee D, Lee S, Doh I, Ryu G, Nam D
. High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform. Biomed Res Int. 2017; 2017:7218707.
PMC: 5705865.
DOI: 10.1155/2017/7218707.
View
7.
Yan X, Zhou L, Wu Z, Wang X, Chen X, Yang F
. High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing. Biomaterials. 2018; 198:167-179.
DOI: 10.1016/j.biomaterials.2018.05.020.
View
8.
Huang Y, Dai Y, Wen C, He S, Shi J, Zhao D
. circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway. Mol Ther Nucleic Acids. 2020; 21:885-899.
PMC: 7452060.
DOI: 10.1016/j.omtn.2020.07.027.
View
9.
Whittaker S, Demierre M, Kim E, Rook A, Lerner A, Duvic M
. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010; 28(29):4485-91.
DOI: 10.1200/JCO.2010.28.9066.
View
10.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R
. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47.
DOI: 10.1016/j.ejca.2008.10.026.
View
11.
Zhang , Chung , OLDENBURG
. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73.
DOI: 10.1177/108705719900400206.
View
12.
Thuss-Patience P, Stein A
. Immunotherapy in Squamous Cell Cancer of the Esophagus. Curr Oncol. 2022; 29(4):2461-2471.
PMC: 9026413.
DOI: 10.3390/curroncol29040200.
View
13.
Thuru X, Magnez R, El-Bouazzati H, Vergoten G, Quesnel B, Bailly C
. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers (Basel). 2022; 14(14).
PMC: 9322126.
DOI: 10.3390/cancers14143368.
View
14.
Foltyn M, Luger A, Lorenz N, Sauer B, Mittelbronn M, Harter P
. The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. Br J Cancer. 2019; 120(5):481-487.
PMC: 6461855.
DOI: 10.1038/s41416-018-0368-3.
View
15.
El Omari N, Lee L, Bakrim S, Makeen H, Alhazmi H, Mohan S
. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin. Biomed Pharmacother. 2023; 164:114774.
DOI: 10.1016/j.biopha.2023.114774.
View
16.
Wang Y, Han E, Xing Q, Yan J, Arrington A, Wang C
. Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer Lett. 2014; 358(2):170-179.
PMC: 5989711.
DOI: 10.1016/j.canlet.2014.12.033.
View
17.
Kim L, Cook R, Chen J
. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2016; 36(16):2191-2201.
PMC: 5393956.
DOI: 10.1038/onc.2016.363.
View
18.
Zeng M, Ruan Z, Tang J, Liu M, Hu C, Fan P
. Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice. Cancer Cell Int. 2023; 23(1):120.
PMC: 10283277.
DOI: 10.1186/s12935-023-02953-3.
View
19.
Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo Y
. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2020; 70(1):61-73.
PMC: 7838139.
DOI: 10.1007/s00262-020-02653-1.
View
20.
Jiang Y, Jiang Y, Li C, Zhang Y, Dakle P, Kaur H
. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. Gastroenterology. 2020; 159(4):1311-1327.e19.
DOI: 10.1053/j.gastro.2020.06.050.
View